Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.
Also called NCT02556918
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 202 participants
- Sponsor
- Registry
-
NCT02556918
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02556918. Randomized; single masking; primary purpose prevention. Start 2016-01 (registry gives no type); primary completion 2018-11-06 (actual). Results posted on 2019-12-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
- Acronym
- SITA-CABGDM
- Condition
- Hyperglycemia
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Regular Human Insulin
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Supplemental insulin (Insulin lispro)
- Intervention (Drug)
- Supplemental insulin (Insulin aspart)
- Lead sponsor
- Emory University
Record details
- Record id
cardio:ct-nct02556918- Content hash
30c5c144179f1968dfcac1991fb3591a46b2d021d458c333357287dc80f5b369